Serratia infections in a general hospital: Characteristics and outcomes

Samonis, G; Vouloumanou, EK; Christofaki, M; Dimopoulou, D; Maraki, S; Triantafyllou, E; Kofteridis, DP; Falagas, ME

dc.contributor.author	Samonis, G	en
dc.contributor.author	Vouloumanou, EK	en
dc.contributor.author	Christofaki, M	en
dc.contributor.author	Dimopoulou, D	en
dc.contributor.author	Maraki, S	en
dc.contributor.author	Triantafyllou, E	en
dc.contributor.author	Kofteridis, DP	en
dc.contributor.author	Falagas, ME	en
dc.date.accessioned	2014-03-01T01:37:04Z
dc.date.available	2014-03-01T01:37:04Z
dc.date.issued	2011	en
dc.identifier.issn	0934-9723	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/21434
dc.subject.classification	Infectious Diseases	en
dc.subject.classification	Microbiology	en
dc.subject.other	amikacin	en
dc.subject.other	amoxicillin plus clavulanic acid	en
dc.subject.other	ampicillin	en
dc.subject.other	aztreonam	en
dc.subject.other	beta lactamase inhibitor	en
dc.subject.other	carbapenem derivative	en
dc.subject.other	cefalotin	en
dc.subject.other	cefotaxime	en
dc.subject.other	cefoxitin	en
dc.subject.other	ceftazidime	en
dc.subject.other	ceftriaxone	en
dc.subject.other	cefuroxime	en
dc.subject.other	chloramphenicol	en
dc.subject.other	cotrimoxazole	en
dc.subject.other	gentamicin	en
dc.subject.other	imipenem	en
dc.subject.other	meropenem	en
dc.subject.other	nalidixic acid	en
dc.subject.other	netilmicin	en
dc.subject.other	nitrofurantoin	en
dc.subject.other	penicillin derivative	en
dc.subject.other	piperacillin	en
dc.subject.other	piperacillin plus tazobactam	en
dc.subject.other	quinoline derived antiinfective agent	en
dc.subject.other	tetracycline	en
dc.subject.other	ticarcillin	en
dc.subject.other	timentin	en
dc.subject.other	tobramycin	en
dc.subject.other	trimethoprim	en
dc.subject.other	unindexed drug	en
dc.subject.other	adult	en
dc.subject.other	antibacterial activity	en
dc.subject.other	antibiotic resistance	en
dc.subject.other	antibiotic sensitivity	en
dc.subject.other	article	en
dc.subject.other	bacterium isolate	en
dc.subject.other	cause of death	en
dc.subject.other	controlled study	en
dc.subject.other	endophthalmitis	en
dc.subject.other	female	en
dc.subject.other	general hospital	en
dc.subject.other	hospital infection	en
dc.subject.other	human	en
dc.subject.other	infant	en
dc.subject.other	keratitis	en
dc.subject.other	major clinical study	en
dc.subject.other	male	en
dc.subject.other	mortality	en
dc.subject.other	nonhuman	en
dc.subject.other	outcome assessment	en
dc.subject.other	outpatient	en
dc.subject.other	priority journal	en
dc.subject.other	respiratory tract infection	en
dc.subject.other	retrospective study	en
dc.subject.other	Serratia infection	en
dc.subject.other	Serratia marcescens	en
dc.subject.other	Adult	en
dc.subject.other	Aged	en
dc.subject.other	Aged, 80 and over	en
dc.subject.other	Anti-Bacterial Agents	en
dc.subject.other	Cross Infection	en
dc.subject.other	Endophthalmitis	en
dc.subject.other	Greece	en
dc.subject.other	Hospitals, General	en
dc.subject.other	Humans	en
dc.subject.other	Keratitis	en
dc.subject.other	Male	en
dc.subject.other	Microbial Sensitivity Tests	en
dc.subject.other	Middle Aged	en
dc.subject.other	Respiratory Tract Infections	en
dc.subject.other	Retrospective Studies	en
dc.subject.other	Serratia Infections	en
dc.subject.other	Serratia marcescens	en
dc.subject.other	Treatment Outcome	en
dc.title	Serratia infections in a general hospital: Characteristics and outcomes	en
heal.type	journalArticle	en
heal.identifier.primary	10.1007/s10096-010-1135-4	en
heal.identifier.secondary	http://dx.doi.org/10.1007/s10096-010-1135-4	en
heal.language	English	en
heal.publicationDate	2011	en
heal.abstract	We aimed to present our experience regarding infections caused by Serratia spp. in a region with relatively high antimicrobial resistance rates. We retrospectively reviewed the databases of the microbiological laboratory of the University Hospital of Heraklion, Crete (2/2004-12/2009). A total of 77 patients [67.5% men, mean age ± standard deviation (SD)=56.9±24.5 years) were identified; 37.7% were outpatients. Sixty-five (84.4%) of the 77 included patients had a Serratia marcescens isolate; the remaining 12 patients had a non-marcescens Serratia spp. The most frequently observed infections were respiratory tract infection (32.5%) and keratitis/endophthalmitis (20.8%). Seventy-three (94.9%) patients were cured. Four deaths were observed; three of them were considered as attributed to the Serratia infection. No difference was found regarding the characteristics and outcomes between patients with Serratia marcescens and non-marcescens infections. In addition, antipseudomonal penicillins and their combinations with beta-lactamase inhibitors, as well as carbapenemes, and fluoroquinolones exhibited high antimicrobial activity against both the tested Serratia marcescens and non-marcescens isolates. Our study adds useful information regarding the characteristics and outcomes of patients with Serratia infection, as well as the susceptibilities of the respective Serratia marcescens and non-marcescens isolates, in a region with relatively high levels of antimicrobial resistance. © 2011 Springer-Verlag.	en
heal.publisher	SPRINGER	en
heal.journalName	European Journal of Clinical Microbiology and Infectious Diseases	en
dc.identifier.doi	10.1007/s10096-010-1135-4	en
dc.identifier.isi	ISI:000289483300007	en
dc.identifier.volume	30	en
dc.identifier.issue	5	en
dc.identifier.spage	653	en
dc.identifier.epage	660	en